Literature DB >> 34202573

Understanding Post Entry Sorting of Adenovirus Capsids; A Chance to Change Vaccine Vector Properties.

Coralie F Daussy1, Noémie Pied1, Harald Wodrich1.   

Abstract

Adenovirus vector-based genetic vaccines have emerged as a powerful strategy against the SARS-CoV-2 health crisis. This success is not unexpected because adenoviruses combine many desirable features of a genetic vaccine. They are highly immunogenic and have a low and well characterized pathogenic profile paired with technological approachability. Ongoing efforts to improve adenovirus-vaccine vectors include the use of rare serotypes and non-human adenoviruses. In this review, we focus on the viral capsid and how the choice of genotypes influences the uptake and subsequent subcellular sorting. We describe how understanding capsid properties, such as stability during the entry process, can change the fate of the entering particles and how this translates into differences in immunity outcomes. We discuss in detail how mutating the membrane lytic capsid protein VI affects species C viruses' post-entry sorting and briefly discuss if such approaches could have a wider implication in vaccine and/or vector development.

Entities:  

Keywords:  SARS-CoV-2; adaptive immunity; adenovirus; autophagy; innate immunity; intracellular trafficking; vaccine vector; virus entry

Mesh:

Substances:

Year:  2021        PMID: 34202573     DOI: 10.3390/v13071221

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  355 in total

1.  Identification of a novel downstream binding protein implicated in late-phase-specific activation of the adenovirus major late promotor.

Authors:  G Mondesert; C Tribouley; C Kedinger
Journal:  Nucleic Acids Res       Date:  1992-08-11       Impact factor: 16.971

2.  Structure and uncoating of immature adenovirus.

Authors:  Ana J Pérez-Berná; Roberto Marabini; Sjors H W Scheres; Rosa Menéndez-Conejero; Igor P Dmitriev; David T Curiel; Walter F Mangel; S Jane Flint; Carmen San Martín
Journal:  J Mol Biol       Date:  2009-06-27       Impact factor: 5.469

3.  Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus.

Authors:  M Makimura; S Miyake; N Akino; K Takamori; Y Matsuura; T Miyamura; I Saito
Journal:  Vaccine       Date:  1996-01       Impact factor: 3.641

4.  A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome.

Authors:  K J Fisher; W M Kelley; J F Burda; J M Wilson
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

5.  Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families.

Authors:  A R Shaw; E B Ziff
Journal:  Cell       Date:  1980-12       Impact factor: 41.582

6.  Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs.

Authors:  A J Berk; F Lee; T Harrison; J Williams; P A Sharp
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

7.  Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.

Authors:  Gary P Kobinger; Heinz Feldmann; Yan Zhi; Gregory Schumer; Guangping Gao; Friederike Feldmann; Steven Jones; James M Wilson
Journal:  Virology       Date:  2005-12-13       Impact factor: 3.616

8.  Pulmonary inflammation induced by incomplete or inactivated adenoviral particles.

Authors:  R D McCoy; B L Davidson; B J Roessler; G B Huffnagle; S L Janich; T J Laing; R H Simon
Journal:  Hum Gene Ther       Date:  1995-12       Impact factor: 5.695

9.  Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit.

Authors:  K Helen Bremner; Julian Scherer; Julie Yi; Michael Vershinin; Steven P Gross; Richard B Vallee
Journal:  Cell Host Microbe       Date:  2009-12-17       Impact factor: 21.023

Review 10.  Latest insights on adenovirus structure and assembly.

Authors:  Carmen San Martín
Journal:  Viruses       Date:  2012-05-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.